Here's Why Nektar Therapeutics (NKTR) is a Great Momentum Stock to Buy

Core Insights - Momentum investing focuses on following a stock's recent price trends, with the aim of buying high and selling higher, capitalizing on established price movements [1] - Nektar Therapeutics (NKTR) currently holds a Momentum Style Score of A, indicating strong potential for momentum-based trading [3][12] Company Performance - NKTR shares have increased by 20.14% over the past week, outperforming the Zacks Medical - Drugs industry, which rose by 4.47% during the same period [6] - Over the past quarter, NKTR shares have risen by 16.89%, and over the last year, they have surged by 272.08%, while the S&P 500 has only increased by 6.25% and 14.29%, respectively [7] - The average 20-day trading volume for NKTR is 603,538 shares, which serves as a bullish indicator when combined with rising stock prices [8] Earnings Outlook - In the past two months, two earnings estimates for NKTR have been revised upwards, while none have been lowered, leading to an increase in the consensus estimate from -$12.37 to -$10.87 [10] - For the next fiscal year, five earnings estimates have moved higher, with no downward revisions, indicating positive sentiment around NKTR's earnings potential [10]